CA-GIANT-PROTOCOL
27.1.2022 16:25:07 CET | Business Wire | Press release
GIANT Protocol, a leading-edge web3 protocol building a decentralized connectivity economy, today announced the release of its Litepaper, laying out the various components of GIANT Protocol’s ambitious proposal to decentralize and democratize access to the internet and financial services through a web3 telecommunications layer. GIANT plans to roll out the first iteration of its mainnet in the first half of 2022, so the publication of the Litepaper marks a critical step in ensuring GIANT Protocol’s commitment to being an open-source, public protocol built to support a globally connected world.
GIANT Protocol made its debut in November 2021, announcing its intention to build a tokenized bandwidth platform that will allow anyone with a mobile phone to access the internet and earn rewards based on their connectivity. With a founding team well-established in the telecom sector, GIANT Protocol intends to leverage existing network providers, allowing it to rapidly scale its network.
In December 2021, GIANT Protocol announced it had successfully raised $5 million in a seed funding round led by leading blockchain investment firm CoinFund. Now, the project is pleased to build on this progress with the publication of the Litepaper.
The Litepaper was co-authored by Suruchi Gupta, Founder, and CEO of Giant Protocol, along with the GIANT team. Speaking of its publication, Ms. Gupta commented: “The GIANT Litepaper lays out in detail the context and strategy for building a global telecommunications network that can deliver the benefits of web3 to everyone. We want it to convey our ultimate vision for GIANT: to make internet access more than a boring utility, transforming it into an exciting opportunity for better, faster, and more accessible internet access and accompanying financialization potential.”
Along with contextualizing the need for a global decentralized connectivity economy, the Litepaper provides an overview of GIANT’s proposal for its core connectivity infrastructure. It also outlines the GIANT tokenomic model and explains the DAO governance structure that will manage the protocol, including the role of the GIANT Protocol Foundation, a non-profit organization dedicated to supporting the protocol.
Finally, it shows what to expect from the first implementation of the GIANT Protocol – a wallet, a consumer software for end users to interact with GIANT, a provider software for network providers to offer internet access via GIANT, and a validator node software.
GIANT Protocol now invites feedback on the Litepaper from interested stakeholders who wish to be involved in the development and adoption of the GIANT Protocol, whether they’re network owners, developers, or data consumers.
To view the Litepaper, please visit https://giantprotocol.org/litepaper/
About GIANT Protocol
GIANT Protocol was founded in 2021 to decentralize and democratize access to the internet and financial services by tokenizing bandwidth. The project partners with telecommunications and connectivity providers across the globe to create a decentralized connectivity economy, allowing anyone with a mobile phone to participate.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220127005732/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom